TOP TEN perturbations for 1553057_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553057_at
Selected probe(set): 1553057_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553057_at (1553057_at) across 6672 perturbations tested by GENEVESTIGATOR:

Langerhans cell histiocytosis study 2 (multisystem) / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):-4.7154846
Number of Samples:2 / 10
Experimental Langerhans cell histiocytosis study 2 (multisystem)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal, multisystem (disseminated) disease. Both patients received chemotherapy. Sites of LCH lesions: subj.ID:1 (skin, lungs, multiple skull, mastoid, gingiva), subj.ID:13 (mandible, skull, vertebrae, recurrent orbit, liver, spleen, pituitary gland).
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

Langerhans cell histiocytosis study 2 (unifocal) / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):-4.5958815
Number of Samples:8 / 10
Experimental Langerhans cell histiocytosis study 2 (unifocal)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with unifocal, single system disease (bone lesion).
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

Langerhans cell histiocytosis study 2 (multifocal) / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):-4.46879
Number of Samples:2 / 10
Experimental Langerhans cell histiocytosis study 2 (multifocal)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal (bone, skin lesions) disease.
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

actinic keratosis study 1 / skin squamous cell carcinoma study 1

Relative Expression (log2-ratio):3.6673002
Number of Samples:10 / 30
Experimental actinic keratosis study 1
Skin biopsy from patients with actinic keratosis (AK). Biopsies of skin tissue from different location were snap frozen with liquid nitrogen upon excision during surgery and stored at -80°C. RNA was extracted from fresh frozen tissue specimens by laser capture microdissection. The AK samples included both immunocompetent and immunosuppressed patients (organ transplant recipients (OTRs) or patient with chronic lymphocytic leukemia) and were estimated to be a minimum 90% enrichment for dysplastic cells.
Control skin squamous cell carcinoma study 1
Primary tumor tissue sample from patients with cutaneous squamous cell carcinoma (cuSCC). Biopsies of tumor tissue from different location were snap frozen with liquid nitrogen upon excision during surgery and stored at -80°C. RNA was extracted from fresh frozen tissue specimens by laser capture microdissection. The cSCC samples included a range of histological diagnoses (well differentiated through to poorly differentiated) from both immunocompetent and immunosuppressed patients (organ transplant recipients (OTRs) or patient with chronic lymphocytic leukemia) and were estimated to be a minimum 90% enrichment for tumor.

cutaneous T-cell lymphoma study 1 (tumor phase) / cutaneous T-cell lymphoma study 1 (patch phase)

Relative Expression (log2-ratio):-3.11792
Number of Samples:4 / 2
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control cutaneous T-cell lymphoma study 1 (patch phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the patch phase.

cutaneous T-cell lymphoma study 1 (tumor phase) / normal skin tissue

Relative Expression (log2-ratio):-2.871603
Number of Samples:4 / 8
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control normal skin tissue
Skin biopsies from healthy individuals.

cutaneous T-cell lymphoma study 1 (tumor phase) / cutaneous T-cell lymphoma study 1 (plaque phase)

Relative Expression (log2-ratio):-2.829732
Number of Samples:4 / 7
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control cutaneous T-cell lymphoma study 1 (plaque phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the plaque phase.

psoriasis study 11 (lesional; brodalumab; 15d; 700mg) / psoriasis study 11 (lesional; baseline)

Relative Expression (log2-ratio):-2.2846437
Number of Samples:8 / 25
Experimental psoriasis study 11 (lesional; brodalumab; 15d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

engineered skin substitute study 2 (late) / engineered skin substitute study 2 (early)

Relative Expression (log2-ratio):2.1501007
Number of Samples:5 / 6
Experimental engineered skin substitute study 2 (late)
Human skin substitutes tissue samples collected after 42 and 56 days after transplantation to athymic mice.
Control engineered skin substitute study 2 (early)
Human skin substitutes tissue samples collected after 3 and 7 days after transplantation to athymic mice.

engineered skin substitute study 2 (intermediate) / engineered skin substitute study 1 (intermediate)

Relative Expression (log2-ratio):2.1279993
Number of Samples:6 / 3
Experimental engineered skin substitute study 2 (intermediate)
Human skin substitutes tissue samples collected after 14 and 28 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (intermediate)
Human skin substitutes tissue samples collected after 7 days in culture.